ASH 2022 | Safety and efficacy of ropeginterferon alfa-2b for pre-fibrotic primary myelofibrosis
Harinder Gill
• 10 Dec 2022
Harinder Gill, MBBS, PDipID, MD, MRCP, FRCPath, FHKCP, FHKAM, The University of Hong Kong, Hong Kong, China, shares some insights into the P1101MF study (NCT04988815), which is evaluating the safety and efficacy of ropeginterferon alfa-2b in patients with pre-fibrotic myelofibrosis (MF). Dr Gill comments on the rate of hematologic response observed and further highlights the promise of this agent for the treatment of MF. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
